Your session is about to expire
← Back to Search
Zimberelimab for Solid Tumors
Study Summary
This trial is testing a new drug to see if it is safe and effective for treating advanced solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I finished my last cancer treatment at least 4 weeks ago and any side effects have stabilized.My brain cancer has not worsened in the last 4 weeks according to MRI results.My cancer has spread, cannot be cured by known treatments, and is TMB-H or immune signature positive.I have not received any live vaccines in the last 4 weeks.I am 18 years old or older.I have been treated with temozolomide before.I am able to understand and sign the consent form.I have been treated with anti-PD-L1 or anti-PD-1 therapy before.I have no active cancers in the last year except for treated and cured local cancers.I had major surgery with general anesthesia over 4 weeks ago.I am fully active or can carry out light work.I stopped taking high doses of steroids or similar medicines more than 2 weeks ago.I have at least one tumor that can be measured and it's not in an area treated with radiation.My organs and bone marrow are working well.I haven't had a heart attack or blood clot in the arteries in the last 6 months.I am currently experiencing stomach or digestive issues.I have an autoimmune disease or have needed steroids or immunosuppressants.
- Group 1: Strata Immune Signature positive
- Group 2: TMB-H
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How widespread is this experiment's implementation?
"This clinical trial is currently running in seventeen different medical centres, including Gunderson Lutheran Medical Center (La Crosse), Southern California Permanente Medical Group (Riverside) and Kaiser Permanente (NorCal) - Roseville. The remaining fourteen sites are located across the country."
Are there still opportunities to participate in this scientific experiment?
"Per information available on clinicaltrials.gov, this research project is not currently seeking out participants. The trial was first published in September 2019 and last updated in October 2022; however, there are 2502 other trials which have ongoing recruitment efforts at present."
What are the potential risks associated with zimberelimab?
"With limited data confirming its efficacy and safety, zimberelimab received a score of 1 on our team's scale. Since this is only a Phase 1 trial, further research will be needed to confirm these results."
Share this study with friends
Copy Link
Messenger